Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A small randomised trial and observation of all patients homozygous for beta-thalassaemia in Britain born in or before 1963 indicated that those patients who had received average weekly doses of more than 4 g of desferrioxamine over the previous few years were less likely to die in the near future than were patients of similar ages who had received less, or no, desferrioxamine.


Journal article


Br Med J (Clin Res Ed)

Publication Date





1081 - 1084


Adolescent, Adult, Child, Child, Preschool, Clinical Trials as Topic, Deferoxamine, Dose-Response Relationship, Drug, Humans, Life Expectancy, Random Allocation, Thalassemia